Related Experiment Video
Updated: Dec 31, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
1Division of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Novel therapies offer new hope for relapsed/refractory acute myeloid leukemia (AML) patients, particularly those unfit for chemotherapy. These advanced treatments show promise for improved outcomes in challenging AML cases.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Relapsed and refractory acute myeloid leukemia (AML) presents significant treatment challenges.
- Elderly patients or those with comorbidities often cannot tolerate traditional salvage chemotherapy.
Purpose of the Study:
- To review recent advances in treating relapsed/refractory AML.
- To highlight novel therapeutic approaches for AML patients unsuitable for standard chemotherapy.
Main Methods:
- Review of early-phase studies on novel chemotherapy combinations.
- Evaluation of hypomethylating agents and targeted therapies in AML treatment.
Main Results:
- Novel treatment strategies, including targeted therapies, demonstrate promising results in relapsed/refractory AML.
- These advances offer viable alternatives for patients unable to receive conventional chemotherapy.
Conclusions:
- Early-phase studies indicate encouraging outcomes with novel targeted therapy combinations for relapsed/refractory AML.
- Larger comparative studies are warranted to confirm the potential of these newer treatments to surpass traditional chemotherapy.
More Related Videos
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...